Business
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translatio
About this update from Neurosense Therapeutics Ltd.
[{"type":"text","content":"Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of experience in neurodegenerative disease research, biomarker-driven clinical development, and translational neuroscience, further strengthening NeuroSense's scientific leadership as it advances PrimeC in ALS and expands its Alzheimer's disease program.","length":721,"tagName":"p"},{"type":"image","alt":"NeuroSense Therapeutics Logo","displaySize":"","headline":null,"caption":"NeuroSense Therapeutics Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":160,"url":"https://media.zenfs.com/en/prnewswire.com/488fd1dd822c4adae2c61a5f94250e7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MN2mGlFDOSbLhtTMpnwDsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/488fd1dd822c4adae2c61a5f94250e7d","width":400,"height":160}}},{"type":"text","content":""Prof. Arnold's depth of experience in biomarker-driven clinical development and translational neuroscience aligns closely with how we are advancing our programs," said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. "His perspective will be valuable as we continue to execute across both Alzheimer's disease and ALS."","length":367,"tagName":"p"},{"type":"text","content":""PrimeC's multi-target mechanism addresses biological pathways that are highly relevant to Alzheimer's disease," said Prof. Steven E. Arnold. "I look forward to reviewing the forthcoming clinical and biomarker data and to contributing to the program as it moves forward."","length":299,"tagName":"p"},{"type":"text","content":"NeuroSense recently concluded its proof-of-concept Alzheimer's disease study (RoAD), with top-line results demonstrating a favorable safety and tol...